Active comparator: continued standard of care therapy  III  Primary (up to 14 days): proportion of participants discharged by day 14‐secondary (up to 10 days): proportion of participants with treatment emergent adverse events leading to study drug discontinuation  NCT04292730/Recruiting, Mar‐May 2020